IP Library › Granted Patent US 11,149,244
Granted Patent B2
US 11,149,244 · App. 15/945,000 · Granted Oct 19, 2021

Three-dimensional bioreactor for T-cell activation and expansion for immunotherapy

Inventor: Jian Ling (Spring Branch, TX)
Assignee: SOUTHWEST RESEARCH INSTITUTE
C12M25/14C07K16/2806C07K16/2809C07K16/2818C12M1/005C12M1/14C12M23/34C12M25/02C12N5/0636
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,149,244
App. No.
15/945,000
Granted
Oct 19, 2021
Kind
B2
Abstract

The present invention relates to the application of a three-dimensional (3D) bioreactor for T-cell expansion for immunotherapy.

Claims (27)

1. A method for T-cell expansion comprising:

supplying a 3D bioreactor of biocompatible polymeric material comprising a plurality of voids having a surface area for cell expansion, said plurality of voids having a diameter D, a plurality of pore openings between said voids having a diameter d, such that D>d and wherein: (a) 90% or more of said voids have a selected void volume (V) that does not vary by more than +/−10.0%; and (b) 90% or more of said pore openings between said voids have a value of d that does not vary by more than +/−10.0%;

providing a polydopamine coating on said bioreactor surface area for cell expansion;

providing a tetrameric protein attached to said polydopamine coating;

providing one or more biotinylated antibodies immobilized on said tetrameric protein;

flowing T-cells through said bioreactor having T-cell receptors where said T-cell receptors bind to said one or more biotinylated antibodies and are activated;

exposing the activated T-cells to a perfusion media containing a signaling molecule to promote T-cell expansion.

2. The method of claim 1 wherein said tetrameric protein comprises avidin or streptavidin.

3. The method of claim 1 wherein said biotinylated antibody comprises anti-CD3 antibody.

4. The method of claim 1 wherein said biotinylated antibody comprises anti-CD3 antibody and anti-CD28 antibody.

5. The method of claim 1 wherein said biotinylated antibody comprises anti-CD3 antibody, anti-CD28 antibody, and anti-CD2 antibody.

6. The method of claim 1 wherein said signaling molecule comprises a cytokine signaling molecule.

7. The method of claim 1 wherein said voids have a diameter (D) of 0.4 mm to 100.0 mm.

8. The method of claim 1 wherein said voids have a diameter (D) of 0.4 mm to 25.0 mm.

9. The method of claim 1 wherein said pores have a diameter (d) in the range of 0.2 mm to 10.0 mm.

10. The method of claim 1 wherein 95.0% or more of said voids indicate a void volume (V) that does not vary by more than +/−10.0%.

11. The method of claim 1 wherein 99.0% to 100% of said voids indicate a void volume (V) that does not vary by more than +/−10.0%.

12. The method of claim 1 wherein 95.0% or more of said pore openings between said voids have a value of d that does not vary by more than +/−10.0%.

13. The method of claim 1 wherein 99.0 to 100% or more of said pore openings between said voids have a value of d that does not vary by more than +/−10.0%.

14. The method of claim 1 wherein at least 90.0% of the voids present have 2 pore openings per void.

15. The method of claim 1 wherein at least 90.0% of the voids present have 8 to 12 pore openings per void.

16. The method of claim 1 wherein said voids have an internal concave surface.

17. The method of claim 1 wherein said voids comprise spherical voids.

18. The method of claim 17 wherein said spherical voids have a packing efficiency of greater than 64.0% in a 3D cylindrical space.

19. The method of claim 1 wherein said 3D bioreactor is formed from a material that has a Tensile Modulus of at least 0.01 GPa.

20. The method of claim 1 wherein said 3D bioreactor is formed from a material not susceptible to hydrolysis during cell cultivation such that the amount of hydrolysis does not exceed 5.0% by weight of the material present.

21. The method of claim 1 wherein said bioreactor has a diameter Φ and a height H and the ratio Φ:H is in the range of greater than 1:1 to 100:1.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 1, 2019
From: LING, JIAN
To: SOUTHWEST RESEARCH INSTITUTE
Reel/Frame 049646/0229 →
Continuity (1)
Related Publication 20190309250A1 · Oct 10, 2019
Cited By (1)
US 12,539,515